We are live on ! Find out more
CCM

CAAS Capital Management Portfolio holdings

AUM $934M
1-Year Est. Return 1.45%
This Fund
S&P 500
This Quarter Est. Return
+26.63%
1 Year Est. Return
+1.45%
3 Year Est. Return
+10.99%
5 Year Est. Return
+150.62%
10 Year Est. Return
–
AUM
$10.5B
AUM Growth
+$6.2B
Cap. Flow
+$4.78B
Cap. Flow %
45.54%
Top 10 Hldgs %
28.07%
Holding
985
New
521
Increased
87
Reduced
60
Closed
171

Top Buys

Rank Stock Value
1
RPRX icon
Royalty Pharma
RPRX
+$153M
2
RUN icon
Sunrun
RUN
+$94.3M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$83.8M
4
DT icon
Dynatrace
DT
+$67.2M
5
ED icon
Consolidated Edison
ED
+$56.8M

Top Sells

Rank Stock Value
1
FSLR icon
First Solar
FSLR
+$71.8M
2
TXG icon
10x Genomics
TXG
+$62.3M
3
CZR icon
Caesars Entertainment
CZR
+$60.8M
4
DNLI icon
Denali Therapeutics
DNLI
+$53.1M
5
PENN icon
PENN Entertainment
PENN
+$42M

Sector Composition

Rank Sector Weight
1 Technology 7.01%
2 Healthcare 6.25%
3 Communication Services 2.7%
4 Consumer Discretionary 2.07%
5 Financials 1.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
META icon
726
Meta Platforms (Facebook)
META
$1.5T
$275K ﹤0.01%
+1,005
New +$276K
PRAX icon
727
Praxis Precision Medicines
PRAX
$8.52B
$275K ﹤0.01%
+333
New +$194K
CHRW icon
728
CALL
C.H. Robinson
CHRW
$17.2B
$272K ﹤0.01%
2,900
– –
FUSN
729
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$272K ﹤0.01%
23,148
-35,250
-60% -$443K
TDOC icon
730
Teladoc Health
TDOC
$1.21B
$271K ﹤0.01%
+1,354
New +$275K
BIIB icon
731
PUT
Biogen
BIIB
$29.8B
$269K ﹤0.01%
1,100
– –
ORPH
732
DELISTED
Orphazyme A/S
ORPH
$268K ﹤0.01%
25,000
– –
LI icon
733
Li Auto
LI
$13.6B
$265K ﹤0.01%
9,205
-440,795
-98% -$12.1M
CHFW.U
734
DELISTED
Consonance-HFW Acquisition Corp. Units, each consisting of one Class A Ordinary Share, and one-third
CHFW.U
$262K ﹤0.01%
+25,000
New +$255K
AMC icon
735
AMC Entertainment Holdings
AMC
$2.54B
$257K ﹤0.01%
+12,141
New +$397K
CSX icon
736
CALL
CSX Corp
CSX
$92.3B
$254K ﹤0.01%
+8,400
New +$241K
LLY icon
737
CALL
Eli Lilly
LLY
$1,000B
$253K ﹤0.01%
1,500
– –
MDB icon
738
CALL
MongoDB
MDB
$28.8B
$251K ﹤0.01%
+700
New +$195K
DMRA
739
Damora Therapeutics, Inc. Ordinary Shares
DMRA
$1.76B
$250K ﹤0.01%
+800
New +$298K
PSTH
740
DELISTED
Pershing Square Tontine Holdings, Ltd.
PSTH
$249K ﹤0.01%
+9,000
New +$217K
OSG
741
Octave Specialty Group
OSG
$255M
$244K ﹤0.01%
+15,880
New +$234K
SPRB
742
Spruce Biosciences
SPRB
$119M
$243K ﹤0.01%
+133
New +$220K
CLX icon
743
CALL
Clorox
CLX
$11.9B
$242K ﹤0.01%
1,200
– –
ONT
744
Onterris Inc
ONT
$795M
$241K ﹤0.01%
7,786
-2,214
-22% -$62.9K
KZR
745
DELISTED
Kezar Life Sciences
KZR
$232K ﹤0.01%
+4,444
New +$247K
GOEV
746
DELISTED
Canoo Inc. Class A Common Stock
GOEV
$225K ﹤0.01%
+35
New +$207K
SKINW
747
DELISTED
The Beauty Health Company Warrant expiring 5/4/2026
SKINW
$220K ﹤0.01%
+83,333
New +$186K
TLRY icon
748
CALL
Tilray
TLRY
$632M
$219K ﹤0.01%
+2,650
New +$193K
DMYD.WS
749
DELISTED
dMY Technology Group, Inc. II Redeemable Warrants, each whole warrant exercisable for one share of C
DMYD.WS
$213K ﹤0.01%
+50,000
New +$106K
FDMT icon
750
4D Molecular Therapeutics
FDMT
$527M
$207K ﹤0.01%
+5,000
New +$206K
28 29
30
31 32

Similar funds

CIG
CCM Investment Group Northfield, Minnesota $946M AUM
TAM
Taurus Asset Management New York $986M AUM 5.04% 1-Year Est. Return
WCF
West Coast Financial Santa Barbara, California $876M AUM 5.74% 1-Year Est. Return
CHP
Cable Hill Partners Portland, Oregon $1.02B AUM 8.59% 1-Year Est. Return
SWC
Spectrum Wealth Counsel Indianapolis, Indiana $833M AUM 10.83% 1-Year Est. Return
KTA
Keeley-Teton Advisors Chicago, Illinois $825M AUM 5.4% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return

CAAS Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, CAAS Capital Management held 985 positions worth $10.5B, up 145% from $4.29B the previous quarter. Its ten largest holdings account for 28% of the portfolio.

CAAS Capital Management deployed $4.78B of net new capital in Q4 2020, opening 521 new positions and adding to 87 existing holdings. Its largest new stake was Sunrun: 1,519,346 shares worth $105M.

By sector, the portfolio is most concentrated in Technology at 7% of assets, down from 7.8% a quarter earlier, followed by Healthcare and Communication Services.

On the sell side, the largest reduction was First Solar, an estimated $71.8M trimmed.

  • CAAS Capital Management's largest Q4 2020 buy was Sunrun: 1,519,346 shares worth $105M.
  • CAAS Capital Management added most to Royalty Pharma in Q4 2020, an estimated $153M increase.
  • CAAS Capital Management's biggest Q4 2020 reduction was First Solar, cutting an estimated $71.8M.
  • CAAS Capital Management fully exited 10x Genomics in Q4 2020, selling an estimated $62.3M.
  • CAAS Capital Management's ten largest holdings make up 28% of its $10.5B portfolio in Q4 2020.
  • CAAS Capital Management opened 521 new positions and closed 171 in Q4 2020.
  • CAAS Capital Management's portfolio value rose 145% quarter-over-quarter to $10.5B.

Based on CAAS Capital Management's 13F filing for Q4 2020, filed 12 Feb 2021.